Drug Profile
EGT 301
Alternative Names: AAV9 iduronate-2-sulfatase gene therapy - Esteve/UAB; EGT-301Latest Information Update: 10 Feb 2023
Price :
$50
*
At a glance
- Originator Universitat Autonoma de Barcelona
- Developer ESTEVE; Universitat Autonoma de Barcelona
- Class Gene therapies
- Mechanism of Action Gene transference; Iduronate sulfatase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Mucopolysaccharidosis II
Most Recent Events
- 10 Feb 2023 EGT 301 is still in preclinical phase for Mucopolysaccharidosis-II in Spain (Parenteral) (ESTEVE pipeline; February 2023)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-II in Spain (Parenteral)
- 25 Feb 2016 Preclinical trials in Mucopolysaccharidosis II in Spain (Parenteral)